News for Healthier Living

Mount Sinai Dermatologist Reports Phase 3 Success for Rocatinlimab in Moderate-to-Severe Eczema

An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, has reported results from the first phase 3 clinical trials of rocatinlimab, a novel treatment for moderate-to-severe atopic dermatitis (eczema). The landmark findings from the ROCKET-IGNITE and ROCKET-HORIZON studies were published today in The Lancet.

November 25, 2025


December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025

November 24 2025

November 23 2025

November 22 2025

November 21 2025

November 20 2025

November 19 2025

November 18 2025